BEIJING, May 15, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2012.
Financial Highlights (year-over-year comparisons to first quarter 2011)
Recent Business Highlights
Dr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "The positive vaccine sales trend continued in the first quarter of 2012, which represented a good start for the year as the domestic vaccine market remains favorable. The positive effects of this market can be seen especially in the sales of Bilive, our combined hepatitis A and B vaccine, which increased by 92% year over year. We attribute this increase primarily to our sales and marketing experience and capabilities accumulated and improved in the private sector of the Chinese vaccine market over the past few years. We believe our increased strength in sales and marketing in the private market will also benefit the commercialization of other key products in our pipeline. Additionally, we are pleased to see that approximately 9% of our sales this quarter were generated from international markets. As our international sales team grows and the GMP standard in China improves, the Company is well positioned to take advantage of the opportunities across international markets. In general, our team will continue executing on its strategies to expand commercialized vaccine product sales."
Dr. Yin continued, "We are committed to advancing the development of our vaccine pipeline, which we believe will contribute to the Company's future growth. In the first quarter of 2012, we have substantially completed the key steps of the Phase III clinical trial for our EV71 vaccine, including the inoculation of, and blood collection from, these volunteers. The HFMD epidemic situation is becoming more serious, which not only indicates how important it is to develop our vaccine, but also allows for collection of sufficient data to evaluate the efficacy of the vaccine candidate in the Phase III study. In parallel with the vaccine development, the preparation of our dedicated EV71 vaccine production plant is underway to ensure that the vaccine is ready for commercial use soon after it is approved. "
Financial Review for First Quarter Ended March 31, 2012An analysis of sales and gross profit is as follows:In USD2012Q1% of sales2011Q1%of salesHepatitis A - Healive1,611,576
49.8%Hepatitis A&B - Bilive4,015,460
-Total sales 5,973,467
100%Cost of sales 2,255,289
34.6%Gross profit 3,718,178
Sales for the first quarter of 2012 were $6.0 million, a 30.3% increase over the same period in 2011. Hepatitis vaccines sales increased by 28.9% year-over-year to $5.6 million, with Bilive sales in the private pay market up 92.4% to $4.0 million. Influenza sales grew by 45.1% year-over-year to $314,000.
Gross profit margin in first quarter of 2012 was 62.2%, which was lower than the gross profit margin of 65.4% in the same period of last year. The planned low production level as the animal vaccine facilities ramped up in the first quarter of 2012 lowered the gross margin. If factored out of the calculation, the gross margin for first quarter 2012 would have been 65.1%. After deducting depreciation of land use rights, amortization of licenses and permits, the gross margin was 61.8% and 62.7% for the first quarter of 2012 and 2011, respectively.
Selling, general and administrative expenses for the first quarter of 2012 represented 72.3% of total sales, compared to 89.6% for the same quarter last year. The reduction of the expenses as a percentage of sales was due to higher export sales with low direct selling costs in the first quarter of 2012. The expenses as a percentage of sales was also impacted by the seasonality of the Company's sales, which, based on historical trends, are typically lower in the first half of the year and expected to increase significantly in the second half of the year.
First quarter 2012 research and development expenses reached $7.3 million, a $5.2 million increase over the same period in 2011. The high research development expenses included $5.6 million for the ongoing EV71 clinical trial and $0.5 million for the pilot production activities underway for the mumps vaccine. Research and development expenses in the quarter reflected the continued progress of the various research and development initiatives intended to drive the Company's pipeline products towards commercialization.
Depreciation of property, plant and equipment and amortization of licenses and permits for first quarter 2012 was $307,000, compared to $384,000 for the same period last year. Although the Company had increased depreciation due to increased additions carried forward from 2011, it benefited from much lower amortization expenses arising from fully amortized license and permits for the inactivated hepatitis A vaccine, which resulted in lower depreciation and amortization expenses in the first quarter of 2012, compared to the same quarter last year.
Total operating expenses for the first quarter 2012 were $11.9 million, compared to $6.5 million for the same quarter last year. The major driver of the higher operating expense was the increase in research and development expenses as the Company advances its pipeline vaccine candidates.
The Company's operating loss was $8.2 million for the first quarter 2012, compared to $3.5 million for the first quarter last year.
Loss before income taxes and non-controlling interests was $7.7 million, compared to $3.4 million in the same quarter last year.
Net loss attributable to stockholders in the first quarter 2012 was $5.6 million, or $0.10 per basic and diluted share, compared to a net loss of $2.8 million, or $0.05 per basic and diluted share, for the same quarter last year.
As of March 31, 2012, cash and cash equivalents totaled $94.5 million, compared to $104.3 million as of December 31, 2011. During the first quarter of 2012, the Company utilized $3.1 million of its cash resources to contribute to its ongoing clinical trial for its proprietary EV71 vaccine. The Company intends to provide the trial with approximately additional $7 million during the remaining quarters of the year. Under the credit line arrangements already in place that cover the ongoing capital needs of the Changping site development, $2.2 million was utilized in the first quarter. Capital expenditure payments to complete the Changping site, which are covered by the same credit line arrangements, are estimated to be around $20 million in the remaining quarters of 2012 and $1.7 million in 2013. Conference Call DetailsThe Company will host a conference call on Tuesday, May 15, 2012 at 8:00 a.m. EDT (May 15, 2012 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments. To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (International). A replay of the call will be available from 11 a.m. EDT on May 15, 2012 to May 29, 2012 at midnight. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (International) and reference the replay pin number 393969.
A live audio webcast of the call will also be available from the investors section on the corporate web site at www.sinovac.com. A webcast replay can be accessed on the corporate website beginning May 15, 2012 and the replay will remain available for 30 days.About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu) and H1N1 influenza (swine flu), as well as animal rabies vaccine for canines. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including vaccines for enterovirus 71 (against hand, foot and mouth disease), pneumococcal conjugate, pneumococcal polysaccharides, mumps and rubella. Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines.Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Helen Yang/Chris Lee
Sinovac Biotech Ltd.
The Ruth Group
The Ruth Group
SINOVAC BIOTECH LTD.Incorporated in Antigua and BarbudaConsolidated Balance SheetsMarch 31, 2012 and 2011(Expressed in U.S. Dollars)March 31, 2012December 31, 2011ASSETSCurrent assets Cash and cash equivalents
104,286,695 Accounts receivable - net19,230,43817,834,407 Inventories9,285,3828,113,428 Prepaid expenses and deposits1,077,5171,804,555Total current assets124,082,984132,039,085Property, plant and equipment77,514,16975,627,881Long-term inventories5,393,5025,248,237Long-term prepaid expenses377,199408,656Prepayments for acquisition of equipment301,936828,902Deferred tax assets424,664419,114Licenses and permits1,314,4231,336,254Total assets$209,408,877$215,908,129LIABILITIES AND EQUITYCurrent liabilities Loans payable
4,713,498 Accounts payable and accrued liabilities25,515,31129,522,495Income tax payable3,373,5893,351,127Deferred revenue332,687429,416 Dividends payable-795106 Deferred research grants1,336,1901,830,566Total current liabilities35,301,08540,642,208Deferred government grants2,647,5772,277,428Loans payable19,453,34217,321,327Due to from related party3,172,957Deferred revenue10,435,27810,369,695Total long term liabilities35,709,15429,968,450Total liabilities71,010,23970,610,658Commitments and contingenciesEQUITYPreferred stock-- Authorized 50,000,000 shares at par value of $0.001 each Issued and outstanding: nilCommon stock54,80454,774 Authorized: 100,000,000 shares at par value of $0.001 each Issued and outstanding: 54,773,961(2010 -54,305,961)Additional paid-in capital105,513,891105,383,346Accumulated other comprehensive income10,541,5619,978,325Statutory surplus reserves11,808,27111,808,271Retained earnings (2,916,828)2,696,227Total stockholders' equity125,001,699129,920,943Non-controlling interests13,396,93915,376,528Total equity138,398,638145,297,471Total liabilities and equity$209,408,877$215,908,129
SINOVAC BIOTECH LTD.Incorporated in Antigua and BarbudaConsolidated Statements of Income (Loss) and Comprehensive Income (Loss)Three months ended March 31, 2012 and 2011(Expressed in U.S. Dollars)Three months endedDecember 3120122011Sales$
4,583,234Cost of sales-(exclusive of depreciation of land-use rights and amortization
of licenses and permits of $25,364 (Three months ended March 31, 2011 - $123,981)2,255,2891,586,017Gross profit3,718,1782,997,217Selling, general and administrative expenses4,320,2894,107,332Research and development expenses - net of
$nil (Three months ended March 31, 2011 - $73,390) in government research grants 7,342,1722,102,381Depreciation of property, plant and equipment and amortization of licenses and permits307,443384,182Government grant recognised as income(71,204)(68,482)Total operating expenses11,898,7006,525,413Operating income (loss)(8,180,522)(3,528,196)Interest and financing expenses (214,320)(69,697)Interest income597,671.00145,374.00Loss on disposal of equipment-(7,704)Other income (expenses)118,078105,969Income (loss) before income taxes and non-controlling interests(7,679,093)(3,354,254)Income tax recovery (expenses) 2,902(310,422)Consolidated net loss(7,676,191)(3,664,676)Less: loss attributable to non-controlling interests2,063,136869,720Net loss attributable to stockholders$(5,613,055)$(2,794,956)Net loss$
(3,664,676)Other comprehensive income Foreign currency translation adjustment646,783839,567Total comprehensive loss(7,029,408)(2,825,109)Less: comprehensive loss attributable to non-controlling interests 1,979,589728,475Comprehensive loss attributable to stockholders$
(2,096,634)Loss per share
(0.05)Weighted average number of shares of common stock outstanding - Basic 54,608,91954,444,077- Diluted54,608,91954,444,077
SINOVAC BIOTECH LTD.Incorporated in Antigua and BarbudaConsolidated Statements of Cash FlowsThree months ended March 31, 2012 and 2011(Expressed in U.S. Dollars)Three months endedMarch 3120122011Cash flows used in operating activities Net income (loss)
Adjustments to reconcile net income to net cash
provided by operating activities: - deferred income taxes(2,902)310,422 - stock-based compensation80,17532,662 - inventory provision85,864- - Provision for (recovery of) doubtful accounts-- - write-down of equipment and loss on disposal-7,704 - unrealized foreign exchange gain(210,581)- - research and development expenditures qualified for government grant(79,113)(73,390) - depreciation of property, plant and equipmentand amortization of licenses and permits1,252,5501,192,706 - deferred government grant recognized in income (71,204)(68,482)
Changes in: - accounts receivable(1,285,806)46,577 - inventories(1,319,475)(2,281,688) - income tax payable 12,210(103,393) - prepaid expenses and deposits782,156(9,231)- deferred revenue (99,517)(302,680) - accounts payable and accrued liabilities(3,404,810)(2,878,114)Net cash used in by operating activities(11,868,253)(7,689,738)Cash flows from (used in) financing activities- Loan proceeds2,023,939-- Proceeds from shares subscribed 3,040-- Exercise of stock options47,360284,709- Dividends paid to non-controlling shareholder of Sinovac Beijing(800,717)(2,456,884)- Loan from non-controlling shareholder of Sinovac Dalian3,175,266-Net cash provided by (used in) financing activities4,448,888(2,172,175)Cash flows used in investing activities - Prepayments for acquisition of equipment-(1,529) - Acquisition of property, plant and equipment(2,960,461)(1,153,348)Net cash provided used in investing activities(2,960,461)(1,154,877)Exchange gain on cash and cash equivalents582,778407,599Decrease in cash and cash equivalents(9,797,048)(10,609,191)Cash and cash equivalents, beginning of period104,286,695101,585,490Cash and cash equivalents, end of period$
90,976,299Supplemental disclosure of cash flow information:Cash paid for interest,net of amounts capitalized
103,393Cash paid for income taxes
306,017Supplemental schedule of non-cash activities:Acquisition of property, plant and equipment included in accounts payable and accrued liabilities
|SOURCE Sinovac Biotech Ltd.|
Copyright©2010 PR Newswire.
All rights reserved